Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | The evolving field of rectal cancer management

Xavier Serra-Aracil • 5 Jun 2022
ASCO 2022
Gastrointestinal Cancer Rectal Cancer

Xavier Serra-Aracil, MD, PhD, Parc Tauli University Hospital, Barcelona, Spain, talks on the management of rectal cancer. Chemoradiotherapy and total mesorectal excision (TME) is the standard treatment for locoregional rectal cancer. However, with novel combinations of chemoradiotherapy, avoiding TME may be possible in the near future. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Xavier Serra-Aracil

0:37
Standard surgical treatment for rectal adenocarcinoma: from TME to CRT-TEM
Xavier Serra-Aracil • 5 Jun 2022
1:18
The TAUTEM study: transanal endoscopic microsurgery vs. total mesorectal excision
Xavier Serra-Aracil • 5 Jun 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals